Despite Gout Numbers and Flares, Allopurinol is Underutilized Save

A population-based survey from South Australia shows that gout flares are common in the community and have a significant effect on health-related quality of life (HRQoL), yet there is significant undertreatment of gout, even in those on current allopurinol.

The South Australia Health Omnibus Survey is an annual, face-to-face adult population-based survey that collected information on self-reported medically diagnosed gout, allopurinol use and gout attacks (flares) in the prior 12 months.

Overall the findings showed:

• the prevalence of gout in the population was 6.5%
• 37.1% of gout patients were on current allopurinol and 23.2% reported prior use
• frequent flares (≥ 2/year) were reported by 25% of gout
  • were more likely with: younger age, higher BMI, and current allopurinol use (p < 0.05)
  • in those with frequent gout flares, 51% were on current allopurinol therapy
• gout flares were associated with a lower physical HRQoL (p = 0.012). 

Despite the prevalence, flares rates and HRQoL effects seen with gout, only 37% were on allopurinol (51% in those with frequent attacks).

Undertreated disease and suboptimal use of urate lowering therapy continue to plaque gout management in the populace.